Collection of Safety, Efficacy and Resource Utilization Information in Patients Who Have Received Melphalan PHP With the Delcath Hepatic Delivery System for the Treatment of Unresectable Hepatic Malignancy
Phase of Trial: Phase IV
Latest Information Update: 20 Sep 2018
At a glance
- Drugs Melphalan (Primary)
- Indications Liver cancer
- Focus Adverse reactions
- Sponsors Delcath Systems
- 07 Sep 2018 Planned End Date changed from 1 Feb 2019 to 1 Feb 2020.
- 07 Sep 2018 Planned primary completion date changed from 1 Jan 2019 to 1 Jan 2020.
- 01 Sep 2017 New trial record